Financial Results for the Fiscal Year
Ended March 31, 2024 (FY2023)

from the beginning

Financial Results for the Fiscal Year Ended March 31, 2024 (FY2023)

• Forward-Looking Statements and Use of Document

• Highlights

• P&L

• OP Variance Analysis (Q4): Profitability improvements as planned

• OP Variance Analysis (Q4YTD): As planned in all areas

• Revenue by Region: Therapeutic devices strong in Americas, Europe: Asia drove high growth rate

• C&V: Continued global demand, driven by double-digit growth in Vascular and Neuro

• TMCS: Increased revenue and profit despite impact of Nutrition business divestiture, return to normal of thermometers

• TBCT: Strong blood center business drove large profit increase

• FY24 Guidance

• Profit Variance Analysis (FY24 Guidance)

• Assumptions Underlying FY24 Guidance

• Dividend Proposal: Continuous increase per shareholder return policy

Reference

• Revenue by Segment and Region

• Quarterly Revenue Trend

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustment Items

• CAPEX, Depreciation and Amortization, R&D Expenses

• Cash Flows (Q4 YTD)

• Cash Flows (Q4)

• FY23 Q4 YTD FX Impact Breakdown (Flow and Stock)

• Foreign Exchange Sensitivity

@

The Future of Terumo "Our vision and the path to it"

• Forward-Looking Statements and Use of Document

• Terumo's mission and creation of corporate value

• Changes in healthcare & society, and Terumo's transformation

• Novel growth we have already achieved

• Revenue and market capitalization

• Terumo's Approach

• Financial soundness in support of M&A

• Improve earning power; enhance corporate value

• Terumo's goals and creation of corporate value

@